Company Overview and News
2018-09-13 247wallst - 1
Short interest moves among solar and alternative energy stocks were mixed during the two-week reporting period that ended on August 31. Of the companies we watch, short interest rose on two of three solar stocks and rose on three of five alternative energy stocks. We’ve added fuel cell maker Bloom Energy to our watch list this week.
SPWR CLNE BE FCELB 5GD SRGRF PEIX FSLR CSIQ PLUG FCEL
2018-09-07 zacks - 1
FuelCell Energy, Inc. (FCEL - Free Report) incurred third-quarter fiscal 2018 adjusted loss of 20 cents per share, wider than the Zacks Consensus Estimate of a loss of 19 cents. However, the loss was narrower than 31 cents recorded in the year-ago quarter. Total Revenues Adjusted revenues of $12.11 million surpassed the Zacks Consensus Estimate of $12 million by 0.9%. Also, the top line improved 17% from the prior-year figure of $10.
CCR ALLY NOG FCELB OUT FCEL
Good morning. My name is Casey and I will be your conference operator today. At this time, I would like to welcome everyone to the FuelCell Energy Q3 2018 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions] Thank you. Tom Gelston, Vice President of Investor Relations, you may begin your conference.
fcel-10q_20180731.htm UNITED STATES
2018-09-03 zacks - 1
Ballard Power Systems, Inc. (BLDP - Free Report) has entered into a definitive agreement with Revision Military Ltd., a private U.S.-based company, to sell certain non-core assets of its subsidiary, Protonex, with regard to its Power Manager business. The company will receive a total of $16 million in cash as sale consideration. However, it will still retain certain assets related to fuel cell propulsion systems for military and commercial unmanned vehicles.
BLD 2338 FCELB WEICF DDAIF PLUG FCEL BLDP WEICY
This is a truncated trading week as the markets are closed on Monday, but that won’t companies from reporting quarterly results later in the week. We already have seen strong earnings from many companies pushing the S&P 500 and Nasdaq to all-time highs. If the markets want to keep up the momentum, companies will have to go on hitting their targets.
MRVL DOCU PANW FCELB CONN RH GME FCEL AVGO SMAR TRI BRCM
2018-08-31 zacks - 2
FuelCell Energy, Inc. (FCEL - Free Report) recently announced that it has sold a turnkey project to AEP OnSite Partners a subsidiary of American Electric Power Company, Inc. (AEP - Free Report) . This project will supply clean power and heat to Trinity College under a multi-year power purchase agreement (PPA). Details of the Project The project company sold by FuelCell Energy is a 1.4-megawatt (MW) fuel cell power plant, located at Trinity College in Connecticut.
FCELB AEP PLUG FCEL BLDP
2018-08-30 zacks - 2
Wall Street expects a year-over-year increase in earnings on higher revenues when FuelCell Energy (FCEL - Free Report) reports results for the quarter ended July 2018. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.
FCELB FIZZ FCEL
DANBURY, Conn., Aug. 30, 2018 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq: FCEL), a global leader in delivering clean, innovative and affordable fuel cell solutions for the supply, recovery and storage of energy, today announced that it has sold the project company that owns the 1.4 megawatt fuel cell power plant located at Trinity College in Connecticut, to AEP OnSite Partners, an American Electric Power (NYSE: AEP) company.
FCELB AEP FCEL
2018-08-29 sec.gov - 9
DANBURY, CONN., Aug. 29, 2018 (GLOBE NEWSWIRE) -- FuelCell Energy, Inc. (Nasdaq:FCEL), a global leader in delivering clean, innovative and affordable fuel cell solutions for the supply, recovery and storage of energy, announced today the completion of an underwritten offering of 30,680 shares of Series D Convertible Preferred Stock (the “Series D Preferred Stock”) with a stated value of $1,000 per share.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to FCEL / FuelCell Energy, Inc. on message board site Silicon Investor.
|FuelCell Energy - going green||FuelCell Energy - going green||FuelCell Energy - going green||FCEL||FCEL||FCEL|
|Fuel Cells||Fuel Cells||Fuel Cells|
as of ET